TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39744861

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg intravenously)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Best medical treatment (including 23% receiving intravenous tissue-type plasminogen activator)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 224
Study: 39744866

Group type: EXPERIMENTAL
Intervention: Silver-coated silicone transurethral indwelling catheters (TICs)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard silicone transurethral indwelling catheters (TICs)
Number of subjects: 310
Study: 39744921

Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 μg orally twice daily for 48 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 39744963

Group type: COMPARATOR
Intervention: PRPP Intervention (9 sessions)
Number of subjects: 3
Study: 39745099

Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT) intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Physical assessments after 6 months of cancer treatment
Number of subjects: 84
Study: 39745261

Group type: EXPERIMENTAL
Intervention: Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System
Number of subjects: 0
Study: 39745289

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 39745404

Group type: EXPERIMENTAL
Intervention: Baseline SBP categories (<120, 120-129, 130-139, and ≥140 mm Hg)
Number of subjects: 16950

Group type: EXPERIMENTAL
Intervention: PP quartiles (reference: 46-54 mm Hg)
Number of subjects: 16950

Group type: EXPERIMENTAL
Intervention: Continuous baseline SBP and PP
Number of subjects: 16950

Group type: EXPERIMENTAL
Intervention: Higher PP
Number of subjects: 16950
Study: 39745520

Group type: EXPERIMENTAL
Intervention: With a chaperone during proctological exam
Number of subjects: 190

Group type: COMPARATOR
Intervention: Without a chaperone during proctological exam
Number of subjects: 190
Study: 39745526

Group type: EXPERIMENTAL
Intervention: Novel PSMA-targeting radiopharmaceutical
Number of subjects: 0
Study: 39745672

Group type: EXPERIMENTAL
Intervention: BBTI training alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BBTI + IS (training plus implementation strategies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39745682

Group type: EXPERIMENTAL
Intervention: Nontransplant salvage therapy (radiotherapy) for low-risk patients (n=41)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HDCT/aSCT off protocol for low-risk patients (n=18)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HDCT/aSCT for high-risk patients (n=59)
Number of subjects: 118
Study: 39745701

Group type: EXPERIMENTAL
Intervention: Parent-targeted oral health text (OHT) messages
Number of subjects: 754

Group type: COMPARATOR
Intervention: Child wellness text (CWT) messages
Number of subjects: 754
Study: 39745702

Group type: EXPERIMENTAL
Intervention: Recombinant quadrivalent influenza vaccine (RIV4)
Number of subjects: 144565

Group type: COMPARATOR
Intervention: Standard egg-based quadrivalent inactivated influenza vaccine (IIV4)
Number of subjects: 144565
Study: 39745739

Group type: EXPERIMENTAL
Intervention: Nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response and involved-site radiotherapy (ISRT) at 30.0 to 30.6 Gy.
Number of subjects: 28
Study: 39746099

Group type: EXPERIMENTAL
Intervention: Tracheal temperature measurement using ETT thermometer
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pulmonary artery catheter (PAC) temperature measurement
Number of subjects: 11
Study: 39746186

Group type: EXPERIMENTAL
Intervention: HPI-guided management
Number of subjects: 917

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 917
Study: 39746206

Group type: EXPERIMENTAL
Intervention: RSVpreF
Number of subjects: 7386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7386
Study: 39746210

Group type: EXPERIMENTAL
Intervention: Standard care plus meditation and yoga (mind-body group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 97
Study: 39746212

Group type: EXPERIMENTAL
Intervention: RSVpreF 120 micrograms
Number of subjects: 7420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7420
Study: 39746387

Group type: EXPERIMENTAL
Intervention: Echocardiography guided (EC)-LBBP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 30
Study: 39746473

Group type: EXPERIMENTAL
Intervention: cQFR <0.875
Number of subjects: 1931

Group type: COMPARATOR
Intervention: cQFR ≥0.875
Number of subjects: 1931

Group type: EXPERIMENTAL
Intervention: cQFR
Number of subjects: 1931
Study: 39746515

Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB) combined with mometasone furoate nasal spray (MFNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 0
Study: 39746883

Group type: EXPERIMENTAL
Intervention: Decision coaching intervention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Decisional Conflict Scale
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 8
Study: 39746964

Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan (HE072) at dose levels of 50, 70, and 90 mg/m²
Number of subjects: 0
Study: 39747123

Group type: EXPERIMENTAL
Intervention: C5/MCD subtype, i/eot-PET-negative status
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: C2/A53 subtype, i/eot-PET-negative status
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Other subtypes (not C5/MCD or C2/A53), i/eot-PET-negative status
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: i/eot-PET-positive status for all subtypes
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: C5 i/eot-PET-negative patients
Number of subjects: 592
Study: 39747681

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 39747856

Group type: EXPERIMENTAL
Intervention: GT103 (0.3 mg/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GT103 (1 mg/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GT103 (10 mg/kg every 3 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GT103 (various doses)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GT103
Number of subjects: 31
Study: 39747932

Group type: EXPERIMENTAL
Intervention: PET/CT targeting prostate-specific membrane antigen (PSMA)
Number of subjects: 0
Study: 39747998

Group type: EXPERIMENTAL
Intervention: Delandistrogene moxeparvovec micro-dystrophin gene therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon-gamma ELISpot assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In silico epitope mapping
Number of subjects: 0
Study: 39748155

Group type: EXPERIMENTAL
Intervention: Doravirine-based regimen (DOR/lamivudine/TDF)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Doravirine-based regimen (DOR + 2 NRTIs)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Doravirine-based regimen (DOR)
Number of subjects: 502
Study: 39748312

Group type: EXPERIMENTAL
Intervention: Zavegepant 10 mg nasal spray
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1269
Study: 39748327

Group type: EXPERIMENTAL
Intervention: Risk score for preterm birth (PTB) based on psychosocial predictors including being unmarried, social support score, intimate partner violence (IPV), and mild-to-severe depressive symptoms (CESD-10 score ≥ 5).
Number of subjects: 4084

Group type: EXPERIMENTAL
Intervention: Predictors of PTB including being unmarried, lower education, IPV (HITS score ≥ 5), higher CESD-10 score, lower social support score, and mild-to-severe depressive symptoms.
Number of subjects: 4084
Study: 39748361

Group type: EXPERIMENTAL
Intervention: Finnish Diabetes Risk Score (FINDRISC) assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index-2015 (HEI-2015) dietary assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Regression model analysis
Number of subjects: 100
Study: 39748396

Group type: EXPERIMENTAL
Intervention: Antenatal breastmilk expression (aBME) for 10 minutes, 2 times daily from week 34 until birth.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no aBME).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Antenatal breastmilk expression (aBME).
Number of subjects: 60
Study: 39748428

Group type: EXPERIMENTAL
Intervention: CD33-targeted CAR-NK cell therapy
Number of subjects: 10
Study: 39748491

Group type: EXPERIMENTAL
Intervention: Liposomal mitoxantrone (Lipo-MIT) monotherapy
Number of subjects: 108
Study: 39748503

Group type: EXPERIMENTAL
Intervention: Motivational interview-based training program (6 sessions)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 76
Study: 39748512

Group type: EXPERIMENTAL
Intervention: Panorama algorithm (context-aware autoscoring)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Conventional context-unaware algorithm
Number of subjects: 266
Study: 39748640

Group type: EXPERIMENTAL
Intervention: Whole-body magnetic resonance imaging (WBM) and multicancer early detection (MCED) testing
Number of subjects: 100
Study: 39748726

Group type: EXPERIMENTAL
Intervention: Yttrium-90 FF-21101 (25 mCi/m)
Number of subjects: 57
Study: 39749040

Group type: EXPERIMENTAL
Intervention: Active tumors group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypertensive lacunar stroke (LS) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive tumors group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-hypertensive embolic stroke (NHES) group
Number of subjects: 0
Study: 39749255

Group type: EXPERIMENTAL
Intervention: Higher Cardiorespiratory Fitness (CRF)
Number of subjects: 0
Study: 39749328

Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-ST (prefusion-stabilized spike protein)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MVA-SARS-2-S (native spike protein)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ChAd vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: mRNA vaccine
Number of subjects: 0
Study: 39749486

Group type: EXPERIMENTAL
Intervention: Virtual reality glasses during childbirth
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no virtual reality intervention)
Number of subjects: 60
Study: 39749517

Group type: EXPERIMENTAL
Intervention: Rainbow 5-plex proviral HIV-1 DNA assay
Number of subjects: 83

Group type: COMPARATOR
Intervention: IPDA
Number of subjects: 83

Group type: COMPARATOR
Intervention: Q4PCR
Number of subjects: 83
Study: 39749555

Group type: EXPERIMENTAL
Intervention: PNF with corticosteroid injection
Number of subjects: 400

Group type: COMPARATOR
Intervention: PNF with saline injection
Number of subjects: 400
Study: 39749571

Group type: EXPERIMENTAL
Intervention: WNT5a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TGF-β
Number of subjects: 0
Study: 39749650

Group type: EXPERIMENTAL
Intervention: APOE ε4 carriers
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: APOE ε4+ AD groups
Number of subjects: 575

Group type: COMPARATOR
Intervention: AD group
Number of subjects: 575

Group type: COMPARATOR
Intervention: non-AD dementia group
Number of subjects: 575
Study: 39749727

Group type: EXPERIMENTAL
Intervention: brexpiprazole 2-4 mg/day
Number of subjects: 1000

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1000
Study: 39749912

Group type: EXPERIMENTAL
Intervention: Early routine left ventricular unloading by transseptal left atrial cannulation within 12 hours after randomization
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional approach permitting rescue transseptal cannulation
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Early routine left ventricular unloading
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 116
Study: 39751879

Group type: EXPERIMENTAL
Intervention: Serplulimab 3 mg/kg plus HLX04 10 mg/kg (first-line)
Number of subjects: 61
Study: 39751937

Group type: EXPERIMENTAL
Intervention: PD-1 blockade-activated neoantigen specific cellular therapy (aNASCT)
Number of subjects: 13
Study: 39751962

Group type: EXPERIMENTAL
Intervention: Neoadjuvant darolutamide plus androgen deprivation therapy (ADT) for six months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neoadjuvant darolutamide plus ADT for six months
Number of subjects: 30
Study: 39751970

Group type: EXPERIMENTAL
Intervention: Esketamine-butorphanol group (Group BK) receiving esketamine 1.5 mg/kg and butorphanol 0.15 mg/kg, azasetron 20 mg.
Number of subjects: 181

Group type: COMPARATOR
Intervention: Butorphanol group (Group B) receiving butorphanol 0.15 mg/kg and azasetron 20 mg (normal saline as control).
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Esketamine-butorphanol group (Group BK).
Number of subjects: 181
Study: 39751989

Group type: EXPERIMENTAL
Intervention: Frail patients with Parkinson's disease
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pre-frail and robust patients
Number of subjects: 90
Study: 39752160

Group type: EXPERIMENTAL
Intervention: Interruptive CDS
Number of subjects: 561

Group type: COMPARATOR
Intervention: Noninterruptive CDS
Number of subjects: 561

Group type: COMPARATOR
Intervention: Baseline rate
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 561
Study: 39752191

Group type: EXPERIMENTAL
Intervention: 2-day multimodal intensive educational intervention (supervision-based online teaching)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention during this period)
Number of subjects: 160
Study: 39752236

Group type: EXPERIMENTAL
Intervention: Kidney Stone Disease management in ADPKD patients
Number of subjects: 0
Study: 39752249

Group type: EXPERIMENTAL
Intervention: Standardized breathing with cardiac biofeedback (BFB)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (PPI)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 482
Study: 39752329

Group type: EXPERIMENTAL
Intervention: PsAID12 score <1.7
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PsAID12 score ≥1.7 to ≤3.1
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PsAID12 score >3.1 to <4.8
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PsAID12 score ≥4.8
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PsAID12 against DAPSA
Number of subjects: 410
Study: 39752644

Group type: EXPERIMENTAL
Intervention: Social media recruitment
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: Dating app recruitment
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: Other digital sources recruitment
Number of subjects: 1227
Study: 39752660

Group type: EXPERIMENTAL
Intervention: CSD surgery
Number of subjects: 88
Study: 39753033

Group type: EXPERIMENTAL
Intervention: ConM SOSIP and ConS UFO immunogens (unmodified or stabilised by chemical cross-linking) followed by Mos3.1 and Mos3.2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mos3.1 and Mos3.2 immunogens
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ConM and ConS immunogens
Number of subjects: 51
Study: 39753245

Group type: EXPERIMENTAL
Intervention: ICU follow-up care bundle including diaries, information packages, and specialised follow-up care at 1 and 3 months post-discharge.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care in the ICU and follow-up with their primary care physician (PCP).
Number of subjects: 20
Study: 39753246

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI (8 cycles)
Number of subjects: 60

Group type: COMPARATOR
Intervention: XELOX (5 additional cycles)
Number of subjects: 60
Study: 39753249

Group type: EXPERIMENTAL
Intervention: Cough Peak Flow (CPF-invol)
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Cough Peak Flow (CPF-vol)
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Cough Peak Flow (CPF-invol) for conscious patients
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Successful extubation cases
Number of subjects: 785
Study: 39753253

Group type: EXPERIMENTAL
Intervention: Medically tailored groceries (MTGs)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medically tailored groceries (MTGs) and food resource coaching
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual pantry services (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All interventions (MTGs, MTGs and food resource coaching, and control)
Number of subjects: 60
Study: 39753262

Group type: EXPERIMENTAL
Intervention: Individualised acute normovolaemic haemodilution (ANH) guided by the West China Liu's Score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current clinical practice (Control group)
Number of subjects: 0
Study: 39753264

Group type: EXPERIMENTAL
Intervention: Voice-based technology (VB) for diabetes distress management
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Voice-based technology (VB)
Number of subjects: 12
Study: 39753269

Group type: EXPERIMENTAL
Intervention: Hand acceleration time (HAT) measured at the radial, ulnar and four hand arteries before and after surgery
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Incidence of HAIDI
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Vascular access patency
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Incidence of complications
Number of subjects: 126
Study: 39753296

Group type: EXPERIMENTAL
Intervention: jaktinib 100 mg two times per day
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: jaktinib 75 mg two times per day
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 39753401

Group type: EXPERIMENTAL
Intervention: Continuous preoperative estimated glomerular filtration rate (eGFR)
Number of subjects: 44034
Study: 39753402

Group type: EXPERIMENTAL
Intervention: Early noninvasive ventilation (NIV)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 524
Study: 39753404

Group type: EXPERIMENTAL
Intervention: Telemedicine support
Number of subjects: 71927

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71927
Study: 39753485

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (10 mg/kg weekly on days 1 and 8 of 21-day cycles)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy
Number of subjects: 9
Study: 39753553

Group type: EXPERIMENTAL
Intervention: Ixazomib, lenalidomide, and dexamethasone
Number of subjects: 55
Study: 39753962

Group type: EXPERIMENTAL
Intervention: Single immunization with 50 GA2-infected mosquitoes (GA2-MB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (mock-immunization)
Number of subjects: 15
Study: 39753970

Group type: EXPERIMENTAL
Intervention: BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood, tested in a 3 + 3 dose-finding study with two dose levels (DLs).
Number of subjects: 9
Study: 39753998

Group type: EXPERIMENTAL
Intervention: Moderate and vigorous physical activity intensity cut-points for hip-, wrist-, thigh-, and lower back worn accelerometer
Number of subjects: 0
Study: 39754101

Group type: EXPERIMENTAL
Intervention: Basic knowledge of AI principles
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Awareness of AI usage in dentistry
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Source of information for AI applications
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Agreement on AI's role in advancing dentistry
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Disagreement on AI replacing dentists
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Approval of AI in undergraduate training
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Approval of AI in postgraduate training
Number of subjects: 384
Study: 39754106

Group type: EXPERIMENTAL
Intervention: Dynamic birth position
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Intrapartum support
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Perineal protection
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Midwife-led Quality Improvement intervention
Number of subjects: 630
Study: 39754114

Group type: EXPERIMENTAL
Intervention: hPH injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (normal saline) injection
Number of subjects: 50
Study: 39754130

Group type: EXPERIMENTAL
Intervention: GenV longitudinal cohort study
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: GenV assessments
Number of subjects: 150000
Study: 39754134

Group type: EXPERIMENTAL
Intervention: Extensor Indicis Proprius to EPL tendon transfer
Number of subjects: 13
Study: 39754157

Group type: EXPERIMENTAL
Intervention: Smartphone-delivered dietary education for 12 weeks
Number of subjects: 129

Group type: COMPARATOR
Intervention: Regular care only (control group)
Number of subjects: 129
Study: 39754194

Group type: EXPERIMENTAL
Intervention: Mind programme (ACT and compassion-based intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support group intervention (active control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (inactive control)
Number of subjects: 0
Study: 39754254

Group type: EXPERIMENTAL
Intervention: Laparoscopic and Endoscopic Cooperative Surgery (LECS)
Number of subjects: 0
Study: 39754470

Group type: EXPERIMENTAL
Intervention: BIS guided group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 39754489

Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Standard care following successful thrombectomy (eTICI 2b ≥50)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase
Number of subjects: 376
Study: 39754648

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 36
Study: 39754932

Group type: EXPERIMENTAL
Intervention: Interleukin 6
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Control group (females)
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Other biomarkers
Number of subjects: 1117
Study: 39754976

Group type: EXPERIMENTAL
Intervention: Triptorelin plus letrozole (L)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Triptorelin plus zoledronic acid + letrozole (ZL)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Tamoxifen (T)
Number of subjects: 1065